目的探讨中心体相关蛋白55(CEP55)在结直肠癌组织中的表达及其与临床病理特征及预后的关系。方法选取2017年8月至2020年8月在唐山市中医医院确诊为结直肠癌并进行手术治疗的126例患者作为研究对象,收集结直肠癌患者术中切除的结直肠癌...目的探讨中心体相关蛋白55(CEP55)在结直肠癌组织中的表达及其与临床病理特征及预后的关系。方法选取2017年8月至2020年8月在唐山市中医医院确诊为结直肠癌并进行手术治疗的126例患者作为研究对象,收集结直肠癌患者术中切除的结直肠癌组织及癌旁组织(距离癌组织>2 cm)标本各126例。通过qPCR、免疫组化实验检测结直肠癌组织及癌旁组织中CEP55的表达,分析结直肠癌组织中CEP55的表达与临床病理特征的关系,采用Kaplan-Meier法绘制生存曲线,并分析结直肠癌组织中CEP55的表达与患者3年总生存率之间的关系。结果结直肠癌组织中CEP55 m RNA的表达高于癌旁组织【(1.0±0.2)vs.(0.6±0.1)】,差异有统计学意义(P<0.001)。免疫组化结果显示,CEP55在结直肠癌组织中的表达高于癌旁组织,结直肠癌组织中CEP55高表达比例高于癌旁组织(P<0.001)。结直肠癌组织中CEP55的表达与TNM分期有关(P<0.05),与性别、年龄、肿瘤分化程度、肿瘤最大直径、淋巴结转移、肿瘤位置、肿瘤浸润深度无关(P>0.05)。Ⅲ+Ⅳ期结直肠癌患者组织中CEP55的表达评分高于Ⅰ+Ⅱ期结直肠癌患者(P<0.001)。CEP55高表达的结直肠癌患者3年总生存率低于CEP55低表达的结直肠癌患者(70.3%vs.88.6%),差异有统计学意义(Log-rankχ^(2)=4.715,P=0.031)。结论CEP55在结直肠癌组织中高表达,与TNM分期有关,可能可以作为结直肠癌的潜在预后生物标志物。展开更多
目的探索中心体蛋白55(centrosome protein 55,CEP55)对膀胱癌细胞增殖能力的影响及相关分子机制。方法利用蛋白免疫印迹检测正常膀胱组织细胞(SV-HUC-1)与膀胱癌细胞(T24)CEP55、H3K9 me3的表达量。将膀胱癌细胞T24分为实验组和对照组...目的探索中心体蛋白55(centrosome protein 55,CEP55)对膀胱癌细胞增殖能力的影响及相关分子机制。方法利用蛋白免疫印迹检测正常膀胱组织细胞(SV-HUC-1)与膀胱癌细胞(T24)CEP55、H3K9 me3的表达量。将膀胱癌细胞T24分为实验组和对照组,实验组细胞转染siRNA-CEP55,对照组细胞转染siRNA-MOCK。利用蛋白免疫印迹实验检测各组细胞CEP55、H3K9、H3K9me3的表达量,利用CCK8实验检测各组细胞的增殖能力。结果蛋白免疫印迹实验结果表明,膀胱癌T24细胞CEP55表达量为0.83±0.15,H3K9me3表达量为1.01±0.19。膀胱上皮SV-HUC-1细胞CEP55表达量为0.35±0.09,H3K9me3表达量为0.44±0.10,膀胱癌细胞CEP55、H3K9me3的表达均高于正常膀胱细胞(均P<0.05)。siRNA-CEP55成功降低膀胱癌细胞T24 CEP55的表达。实验组T24细胞吸光度为1.109±0.105,明显低于对照组细胞的2.208±0.104,CEP55低表达会降低T24细胞的增殖能力(P<0.05)。蛋白免疫印迹结果显示实验组T24细胞H3K9变化不明显,H3K9me3表达(P<0.05)明显下降。结论CEP55能通过降低H3K9的三甲基化来抑制膀胱癌细胞的增殖能力。展开更多
Background:Dysregulated expression of centrosomal protein 55(CEP55)has been detected in multiple types of cancers.However,the clinical value of CEP55 expression in cancer is controversial.The current meta-analysis qua...Background:Dysregulated expression of centrosomal protein 55(CEP55)has been detected in multiple types of cancers.However,the clinical value of CEP55 expression in cancer is controversial.The current meta-analysis quantitatively investigated the association between CEP55 expression and prognostic outcomes in cancers.Methods:A literature search was performed using the Chinese National Knowledge Infrastructure(CNKI),Wanfang databases,Web of Science,Embase,MEDLINE,PubMed,and Cochrane Library for primary studies.The pooled hazard ratios(HRs)and odds ratios(ORs)were used to investigate the association between CEP55 expression and its prognostic and clinicopatho-logical value in cancers.Results:A total of 12,543 patients from 31 studies were included in this meta-analysis.High CEP55 expression was significantly associated with poor dif-ferentiation,deeper tumor invasion and increased lymph node metastasis in cancer patients.The pooled results indicated that elevated CEP55 expression can predict a poor overall survival(OS)and disease-free survival(DFS)in cancers.These results should be interpreted with caution because of publi-cation bias.However,the pooled HR for OS of lung cancers was 1.50(95%CI=1.36-1.67,p<0.01)with no heterogeneity and publication bias.Conclusions:CEP55 overexpression correlated with poor cancer differentia-tion,deeper tumor invasion,and increased lymph node metastasis,suggesting that CEP55 may serve as a predictive and prognostic biomarker for cancers,especially for lung cancers.展开更多
文摘目的探讨中心体相关蛋白55(CEP55)在结直肠癌组织中的表达及其与临床病理特征及预后的关系。方法选取2017年8月至2020年8月在唐山市中医医院确诊为结直肠癌并进行手术治疗的126例患者作为研究对象,收集结直肠癌患者术中切除的结直肠癌组织及癌旁组织(距离癌组织>2 cm)标本各126例。通过qPCR、免疫组化实验检测结直肠癌组织及癌旁组织中CEP55的表达,分析结直肠癌组织中CEP55的表达与临床病理特征的关系,采用Kaplan-Meier法绘制生存曲线,并分析结直肠癌组织中CEP55的表达与患者3年总生存率之间的关系。结果结直肠癌组织中CEP55 m RNA的表达高于癌旁组织【(1.0±0.2)vs.(0.6±0.1)】,差异有统计学意义(P<0.001)。免疫组化结果显示,CEP55在结直肠癌组织中的表达高于癌旁组织,结直肠癌组织中CEP55高表达比例高于癌旁组织(P<0.001)。结直肠癌组织中CEP55的表达与TNM分期有关(P<0.05),与性别、年龄、肿瘤分化程度、肿瘤最大直径、淋巴结转移、肿瘤位置、肿瘤浸润深度无关(P>0.05)。Ⅲ+Ⅳ期结直肠癌患者组织中CEP55的表达评分高于Ⅰ+Ⅱ期结直肠癌患者(P<0.001)。CEP55高表达的结直肠癌患者3年总生存率低于CEP55低表达的结直肠癌患者(70.3%vs.88.6%),差异有统计学意义(Log-rankχ^(2)=4.715,P=0.031)。结论CEP55在结直肠癌组织中高表达,与TNM分期有关,可能可以作为结直肠癌的潜在预后生物标志物。
文摘目的探索中心体蛋白55(centrosome protein 55,CEP55)对膀胱癌细胞增殖能力的影响及相关分子机制。方法利用蛋白免疫印迹检测正常膀胱组织细胞(SV-HUC-1)与膀胱癌细胞(T24)CEP55、H3K9 me3的表达量。将膀胱癌细胞T24分为实验组和对照组,实验组细胞转染siRNA-CEP55,对照组细胞转染siRNA-MOCK。利用蛋白免疫印迹实验检测各组细胞CEP55、H3K9、H3K9me3的表达量,利用CCK8实验检测各组细胞的增殖能力。结果蛋白免疫印迹实验结果表明,膀胱癌T24细胞CEP55表达量为0.83±0.15,H3K9me3表达量为1.01±0.19。膀胱上皮SV-HUC-1细胞CEP55表达量为0.35±0.09,H3K9me3表达量为0.44±0.10,膀胱癌细胞CEP55、H3K9me3的表达均高于正常膀胱细胞(均P<0.05)。siRNA-CEP55成功降低膀胱癌细胞T24 CEP55的表达。实验组T24细胞吸光度为1.109±0.105,明显低于对照组细胞的2.208±0.104,CEP55低表达会降低T24细胞的增殖能力(P<0.05)。蛋白免疫印迹结果显示实验组T24细胞H3K9变化不明显,H3K9me3表达(P<0.05)明显下降。结论CEP55能通过降低H3K9的三甲基化来抑制膀胱癌细胞的增殖能力。
基金The 2022 Shenzhen Third People's Hospital Second Batch Medicine Research Project,Grant/Award Number:G2022129。
文摘Background:Dysregulated expression of centrosomal protein 55(CEP55)has been detected in multiple types of cancers.However,the clinical value of CEP55 expression in cancer is controversial.The current meta-analysis quantitatively investigated the association between CEP55 expression and prognostic outcomes in cancers.Methods:A literature search was performed using the Chinese National Knowledge Infrastructure(CNKI),Wanfang databases,Web of Science,Embase,MEDLINE,PubMed,and Cochrane Library for primary studies.The pooled hazard ratios(HRs)and odds ratios(ORs)were used to investigate the association between CEP55 expression and its prognostic and clinicopatho-logical value in cancers.Results:A total of 12,543 patients from 31 studies were included in this meta-analysis.High CEP55 expression was significantly associated with poor dif-ferentiation,deeper tumor invasion and increased lymph node metastasis in cancer patients.The pooled results indicated that elevated CEP55 expression can predict a poor overall survival(OS)and disease-free survival(DFS)in cancers.These results should be interpreted with caution because of publi-cation bias.However,the pooled HR for OS of lung cancers was 1.50(95%CI=1.36-1.67,p<0.01)with no heterogeneity and publication bias.Conclusions:CEP55 overexpression correlated with poor cancer differentia-tion,deeper tumor invasion,and increased lymph node metastasis,suggesting that CEP55 may serve as a predictive and prognostic biomarker for cancers,especially for lung cancers.
